Chronic Obstructive Pulmonary Disease (COPD)
COPD is a disease of the lungs associated with:
- an imbalance in immune function of in the lungs, caused by
- oxidative stressor substances within tobacco smoke and airborne pollutants
The result for the patient is:
- chronic congestion of the lungs
- bronchitis and
- gradual worsening of the condition
Some 14 million people are treated for the condition globally.
Our drugs under development aim to treat COPD in 2 unique, complementary ways:
1. TA-270:
- Dual action, nonsteroidal anti-inflammatory effects combined with reduction in oxidative stress
- Reduces chronic inflammation
- Daily oral treatment to improve lung capacity
2. HI-164:
- Oral vaccine, taken as a single course each year to reduce bacterial levels
- Reduce episodes of acute bronchitis
The drugs are complementary with existing treatments. The attached links provide more detailed information on COPD and the mechanisms of our drugs under development.
Links